X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
DISHMAN PHARMACEUTICALS & CHEMICALS LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

DISHMAN PHARMACEUTICALS & CHEMICALS LTD.  (DHPH)


Here is the latest financial fact sheet of Dishman Pharma. For more details, see the Dishman Pharma quarterly results and Dishman Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
dishman pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 331.7       No. of shares m 161.39
    Mkt Cap Rs m 53,526       % ch % 0.9
    Vol '000 150.0       % ch week % -2.3
    P/E X 26.7       % ch 1-mth % 41.5
    P/CF X 19.8       % ch 12-mth % 85.5
    EPS (TTM) Rs 12.4       52 week H/L Rs 346.3/127.6
(As on Apr 24, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs230107122107183 
Low Rs8935423983 
Sales per share (Unadj.) Rs127.8139.3157.7171.7195.2 
Earnings per share (Unadj.) Rs9.97.012.413.514.8 
Diluted earnings per shareRs5.03.56.26.87.4 
Cash flow per share (Unadj.) Rs18.416.522.827.033.5 
Dividends per share (Unadj.) Rs1.201.201.201.202.00 
Adj. dividends per shareRs0.600.600.600.601.00 
Dividend yield (eoy) %0.81.71.51.61.5 
Book value per share (Unadj.) Rs109.0115.3128.2146.4153.4 
Adj. book value per shareRs54.557.764.173.276.7 
Shares outstanding (eoy) m80.6980.6980.6980.6980.69 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x1.20.50.50.40.7 
Avg P/E ratio x16.110.16.65.48.9 
P/CF ratio (eoy) x8.74.33.62.74.0 
Price / Book Value ratio x1.50.60.60.50.9 
Dividend payout %12.117.19.78.913.5 
Avg Mkt Cap Rs m12,8705,7296,6175,90210,691 
No. of employees `0001.01.01.10.90.9 
Total wages/salary Rs m2,8042,9413,5094,1234,232 
Avg. sales/employee Rs Th10,262.211,541.312,059.014,848.018,273.7 
Avg. wages/employee Rs Th2,789.83,019.63,326.24,419.44,909.6 
Avg. net profit/employee Rs Th796.1582.8950.61,171.21,389.9 
  INCOME DATA
Net Sales Rs m10,31411,24112,72213,85315,752 
Other income Rs m139129178249860 
Total revenues Rs m10,45211,37012,90014,10216,612 
Gross profit Rs m2,0142,2452,9013,3213,136 
Depreciation Rs m6887658381,0861,507 
Interest Rs m557729788921897 
Profit before tax Rs m9088791,4531,5641,593 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m108312450471394 
Profit after tax Rs m8005681,0031,0931,198 
Gross profit margin %19.520.022.824.019.9 
Effective tax rate %11.935.431.030.124.8 
Net profit margin %7.85.07.97.97.6 
  BALANCE SHEET DATA
Current assets Rs m5,8096,2396,7338,24510,135 
Current liabilities Rs m6,8466,5477,1279,02811,048 
Net working cap to sales %-10.1-2.7-3.1-5.7-5.8 
Current ratio x0.81.00.90.90.9 
Inventory Days Days968797112104 
Debtors Days Days6061213850 
Net fixed assets Rs m13,11314,39114,57915,71715,705 
Share capital Rs m161161161161161 
"Free" reserves Rs m7,9088,2259,05110,03111,167 
Net worth Rs m8,7929,30710,34511,81312,378 
Long term debt Rs m4,4435,1214,3364,1213,302 
Total assets Rs m20,84322,49022,91126,27728,089 
Interest coverage x2.62.22.82.72.8 
Debt to equity ratio x0.50.60.40.30.3 
Sales to assets ratio x0.50.50.60.50.6 
Return on assets %6.55.87.87.77.5 
Return on equity %9.16.19.79.39.7 
Return on capital %11.111.115.315.615.9 
Exports to sales %26.930.328.327.822.8 
Imports to sales %12.57.24.76.35.7 
Exports (fob) Rs m2,7723,4043,5953,8553,598 
Imports (cif) Rs m1,292806599869891 
Fx inflow Rs m2,9533,9744,2103,9664,232 
Fx outflow Rs m1,390905695954974 
Net fx Rs m1,5633,0693,5153,0113,258 
  CASH FLOW
From Operations Rs m 2,028 1,536 1,651 3,445 2,858 
From Investments Rs m -2,312 -1,040 -1,173 -2,568 -1,497 
From Financial Activity Rs m 255 -680 -502 -741 -1,425 
Net Cashflow Rs m -29 -185 -23 136 -64 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for dishman pharmaceuticals & chemicals ltd.

 Share Holding
Indian Promoters : 61.4%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 3.7%
FIIs : 12.7%
ADR/GDR : 0.0%
Free float : 22.1%
Shareholders : 46,261
Pledged promoter(s) holding : 35.8%
 Company Information
Top
    REGD OFF: Bhadr-Raj Chambers, Swastik Cross Road, Navrangpura, Ahmedabad - 380 009
    E-MAIL: tushar.shah@dishmangroup.com     WEB: www.dishmangroup.com
    TELEPHONE: (079) 2644 3053     FAX: (079) 2642 0198
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Comp., LBS Marg, Mumbai-78
    AUDITOR: Deloitte Haskins & Sells
CHM: Janmejay R. Vyas (MD) COMP SEC: Tushar D. Shah YEAR OF INC: 1983 BSE CODE: 532526 FV (Rs): 2 DIV YIELD (%): 0.3

More pharmaceuticals Company Fact Sheets:   WOCKHARDT LTD.SUVEN LIFENOVARTISALEMBIC LTDSUN PHARMA


Today's Market

Strong Start to the Week; Cement Stocks Rally(Closing)

Share markets in India finished on a strong footing tracking positive trend in global markets after the market's favored candidate, Emmanuel Macron, won the first round of the French presidential election.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

Why Suddenly There is No Cash in ATMs(Vivek Kaul's Diary)

Apr 11, 2017

There have been a spate of media reports around ATMs not dispensing cash. What is really happening here?

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

Is PPF As An Investment Avenue Dead?(Outside View)

Apr 11, 2017

It's true, the interest on PPF has been lowered to 7.9%. PersonalFN evaluates if it's still a promising investment avenue.

More

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - MYLAN COMPARISON

Compare Company With Charts

COMPARE DISHMAN PHARMA WITH

MARKET STATS